AOD-9604
Metabolic · Growth hormone fragment 176-191
No approved therapeutic indication; research use only.
Robinhood Telehealth family of companies
37 compounds with family, category and current U.S. regulatory status. Status information is summarized for reference and changes over time.
Showing 37 of 37
Metabolic · Growth hormone fragment 176-191
No approved therapeutic indication; research use only.
Reproductive · Oxytocin receptor antagonist
Used in Europe for preterm labor; not FDA approved.
Recovery · Body protective compound pentadecapeptide
Placed in FDA compounding Category 2; research use only.
Metabolic · Long-acting amylin analog
Investigational; studied alone and combined with semaglutide.
Reproductive · Long-acting oxytocin analog
Approved in other countries; not FDA approved in the U.S.
Reproductive · GnRH antagonist
Approved to prevent premature ovulation during fertility treatment.
Hormone · GHRH analog
Compounding restricted; research use only.
Diagnostic · Synthetic ACTH fragment
Approved for adrenal function testing.
Cognitive · Neuromodulatory nonapeptide
No approved indication; early research only.
Metabolic · GLP-1 receptor agonist
Weekly injectable approved for type 2 diabetes.
Metabolic · GLP-1 receptor agonist
Approved for type 2 diabetes; extended-release form discontinued in some markets.
Reproductive · GnRH antagonist
Approved for controlled ovarian stimulation cycles.
Dermatology · Copper tripeptide
Cosmetic use only; no approved therapeutic indication.
Hormone · Growth hormone releasing peptide
No approved indication; research use only.
Hormone · Growth hormone releasing peptide
No approved indication; research use only.
Metabolic · Pancreatic hormone
Approved for severe hypoglycemia rescue.
Reproductive · GnRH decapeptide
U.S. products discontinued; available through compounding only.
Oncology · GnRH agonist implant
Approved for prostate and breast cancer and endometriosis.
Hormone · Growth hormone releasing peptide
Investigational only; no marketing approval.
Hormone · Selective growth hormone secretagogue
Removed from bulk compounding lists; research use only.
Reproductive · KISS1R agonist
Investigational; studied in fertility and sexual function research.
Reproductive · GnRH agonist
Approved for prostate cancer, endometriosis and central precocious puberty.
Metabolic · GLP-1 receptor agonist
Daily injectable approved for diabetes and weight management.
Metabolic · GLP-1 receptor agonist
Approved for type 2 diabetes; limited U.S. availability.
Diagnostic · Oral ghrelin agonist
Approved as a diagnostic test for adult growth hormone deficiency.
Hormone · Oral ghrelin mimetic (non-peptide)
Never approved; sold as a research chemical.
Reproductive · Nonapeptide hormone
Approved injectable for labor induction and postpartum bleeding.
Recovery · Semi-synthetic polysaccharide
Approved for interstitial cystitis; retinal toxicity warnings apply.
Metabolic · Amylin analog
Approved as mealtime adjunct to insulin therapy.
Reproductive · Melanocortin receptor agonist
Approved for hypoactive sexual desire disorder in premenopausal women.
Metabolic · GLP-1 / GIP / glucagon tri-agonist
Investigational; late-stage weight and metabolic trials, no marketing approval.
Metabolic · GLP-1 receptor agonist
Approved prescription medicine for type 2 diabetes and chronic weight management.
Hormone · GHRH (1-29) analog
Former approved product withdrawn commercially; now compounded only.
Metabolic · MC4R agonist
Approved for specific genetic causes of obesity.
Recovery · Actin-binding peptide fragment
Compounding restricted; research use only.
Hormone · GHRH analog
Approved for HIV-associated lipodystrophy.
Metabolic · GLP-1 / GIP dual agonist
Approved prescription medicine for type 2 diabetes and chronic weight management.